<DOC>
	<DOCNO>NCT02292550</DOCNO>
	<brief_summary>This Phase Ib/II study ALK inhibitor ceritinib combination CDK4/6 inhibitor LEE011 patient ALK-positive non-small cell lung cancer . The purpose study determine MTD/RP2D LEE011 ceritinib combination evaluate whether combination safe beneficial effect ALK-positive advanced non-small cell lung cancer patient .</brief_summary>
	<brief_title>Study Safety Efficacy LEE011 Ceritinib Patients With ALK-positive Non-small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Patients must diagnose ALKpositive advance NSCLC . The tumor must ALKpositive determined ALK rearrangement ≥15 % cell ( measure FISH use Vysis breakapart ALK probe ) use Ventana ALK IHC test . The analysis may perform locally . Eastern cooperative oncology group ( ECOG ) performance status ≤ 2 . Measurable disease per RECIST v1.1 Availability tumor sample : For ALK inhibitor naïve patient : A representative tumor sample must submit . An archival tumor specimen acceptable For patient progression ALK inhibitor : A new tumor biopsy require unless biopsy perform progression patient 's recent ALK inhibitor available submission For patient newly obtain tumor specimen must submit appropriate archival sample available . In event sample available new biopsy obtain , enrollment may consider discussion sponsor . For Phase I part : Patients previously receive least one line therapy ALKpositive NSCLC For Phase II part : Group A : prior therapy ALK inhibitor permit . Group B : progression follow ALK inhibitor ( ) ceritinib require last dose ALK inhibitor must 60 day prior first dose study drug . Prior ceritinib permit . Group C : progression follow ceritinib require last dose ceritinib must 60 day prior first dose study drug . Patients previously unable tolerate ceritinib , opinion investigator . Exceptions exclusion include nausea , vomit diarrhea patient take ceritinib fast condition . Patients symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid local CNSdirected therapy control CNS disease Patients abnormal laboratory value screen day 1 predose Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption ceritinib LEE011 Patients currently receive treatment ( discontinue least 1 week prior initiation study ) agent know follow : strong inducer inhibitor CYP3A4/5 ; sensitive substrate CYP3A ; substrates CYP3A4/5 CYP2C9 narrow therapeutic index . Patient history pancreatitis history increase amylase lipase due pancreatic disease . Patient impair cardiac function clinically significant uncontrolled cardiac disease , and/or , cardiac repolarization abnormality , include follow : Clinically significant heart disease CHF require treatment ( NYH grade ≥ 2 ) , history angina pectoris , myocardial infarction , symptomatic pericarditis , coronary artery bypass graft ( CABG ) within 6 month prior study entry , document cardiomyopathy , leave ventricular ejection fraction ( LVEF ) &lt; 50 % determined multiple gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) . Uncontrolled systolic blood pressure ( SBP ) ≥160 mmHg and/or diastolic blood pressure ( DBP ) ≥100 mmHg , without antihypertensive medication . Initiation adjustment antihypertensive medication ( ) allow prior screening , Systolic blood pressure ( SBP ) &lt; 90 mmHg Standard 12lead ECG value define mean triplicate ECGs assess central laboratory QTcF interval screen &gt; 450 msec ( use Fridericia 's correction ) Resting heart rate &lt; 50 bpm &gt; 90 bpm Long QT syndrome family history idiopathic sudden death congenital long QT syndrome , follow : Risk factor Torsades de Pointe ( TdP ) include uncorrected hypokalemia hypomagnesemia , history cardiac failure , history clinically significant/symptomatic bradycardia Concomitant medication ( ) know risk prolong QT interval and/or know cause Torsades de Pointe discontinue replace safe alternative medication ( e.g . within 5 halflives 7 day prior start study drug ) Inability determine QTcF interval Clinically significant cardiac arrhythmia ( e.g. , ventricular tachycardia ) , complete leave bundle branch block , highgrade AV block ( e.g. , bifascicular block , Mobitz type II third degree AV block ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-small cell lung cancer ,</keyword>
	<keyword>ALK translocation ,</keyword>
	<keyword>ALK-positive ,</keyword>
	<keyword>NSCLC ,</keyword>
	<keyword>LEE011 ,</keyword>
	<keyword>CDK4/6 inhibitor ,</keyword>
	<keyword>EML4-ALK</keyword>
</DOC>